Tracer library / [211At]At-astato-benzylguanidine
[211At]At-astato-benzylguanidine
Also written as [At-211]astato-benzylguanidine; [At-211]astatobenzylguanidine; [At-211]At-astatobenzylguanidine
- Radionuclide
- At-211 t½ 431 min
- Modality
- Therapy
- Production route
- —
- Stage
- —
- Syntheses indexed
- 1
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | HPLC | 62.6 ± 2.3% | 97.8% | Boc2-SGMTB tin precursor | 29031230 2018 Nucl Med Biol Astatine-211 in NCS/methanol (30–56 MBq) was added to a vial containing 200 μg of the required tin precursor followed by 10 μL acetic acid. - The radiochemical yield for the synthesis of iso-[211At]SAGMB-Boc2 was 66.8 ± 2.4% (n=7) compared with 62.6 ± 2.3% (n=6) for [211At]SAGMB-Boc2 under identical conditions. |
Need this precursor?We can point you to suppliers for [211At]At-astato-benzylguanidine, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 4 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty.